ProQR Therapeutics (PRQR) Other Accumulated Expenses (2013 - 2026)

ProQR Therapeutics has reported Other Accumulated Expenses for 11 years, with the latest figure at $5.2 million in Q3 2023.

• Quarterly Other Accumulated Expenses fell 62.05% year-over-year to $5.2 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $5.2 million (down 62.05% YoY) and the FY2022 annual result came in at $8.9 million, down 30.4% from the prior year.
• Other Accumulated Expenses improved to $5.2 million in Q3 2023 per PRQR's latest filing, from $4.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $13.8 million in Q3 2022 and troughed at $9.49 in Q1 2019.
• A 5-year average of $7.5 million and a median of $7.8 million in 2020 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2019 and 2021: Other Accumulated Expenses jumped 124844949.54% in 2019, then tumbled 99.92% in 2021.
• Over 5 years, Other Accumulated Expenses stood at $9.8 million in 2019, then retreated by 25.22% to $7.3 million in 2020, then soared by 68.75% to $12.3 million in 2021, then declined by 28.0% to $8.9 million in 2022, then plunged by 40.87% to $5.2 million in 2023.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $5.2 million, $4.4 million, and $5.3 million for Q3 2023, Q2 2023, and Q1 2023 respectively.